# Giulia Siravegna

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/giulia-siravegna/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,432 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 49 |
| i10-index | 66 |
| Last Known Institution | Natera (United States) |
| OpenAlex ID | https://openalex.org/A5031332948 |
| ORCID iD | https://orcid.org/0000-0002-7132-6484 |
| Works | 312 |

## Researcher papers

- [Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies](https://scholariq.org/papers/detection-of-circulating-tumor-dna-in-early-and-late-stage-human-malignancies/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition](https://scholariq.org/papers/tumor-cells-can-follow-distinct-evolutionary-paths-to-become-resistant-to/)
- [Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma](https://scholariq.org/papers/polyclonal-secondary-i-fgfr2-i-mutations-drive-acquired-resistance-to-fgfr/)
- [Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation](https://scholariq.org/papers/clinical-acquired-resistance-to-krasg12c-inhibition-through-a-novel-kras-switch/)
- [Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer](https://scholariq.org/papers/minimal-residual-disease-detection-using-a-plasma-only-circulating-tumor-dna/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)

## Researcher university

- [Natera (United States)](https://scholariq.org/institutions/natera-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.